Abstracts tagged "Disease Activity"

Abstract Number: 0297 • ACR Convergence 2025
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc¹, Marie Hudson¹, Ana Cristina Gonzalez Sanchez², Lina Marcela Diaz Gallo² and Valerie Leclair³, ¹McGill University, Montréal, QC, Canada, ²Karolinska Institutet, Stockholm, Sweden, ³McGill University, Montréal, Canada
Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
Abstract Number: 2650 • ACR Convergence 2025
LFA-REAL Outperforms SLEDAI and BILAG in Detecting Clinical Change in Lupus Activity
Alberto Nordmann-Gomes¹, Leila Khalili², Cynthia Aranow³, Meghan mackay⁴, Mimi Kim⁵, Diane Kamen⁶, Cristina Arriens⁷, Maya Souvignier⁸, Wei Tang⁹, Stephen Suh⁸, Maria Dall'Era¹⁰, Joan Merrill¹¹ and Anca Askanase², ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Johns Island, SC, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Westchester Medical Center, Valhalla, NY, ¹⁰Division of Rheumatology, University of California, San Francisco, CA, ¹¹Oklahoma Medical Research Foundation, Oklahoma
Background/Purpose: Disease activity measures in SLE have important limitations that restrict their performance in clinical practice and research. The Lupus Foundation of America-Rapid Evaluation of…
Abstract Number: 2332 • ACR Convergence 2025
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
Dafne capelusnik¹, Clementina López Medina², Désirée Van Der Heijde³, Daniel Aletaha⁴, Josef Smolen⁵, Anna Molto⁶ and Sofia Ramiro⁷, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Medical University Vienna, Wien, Austria, ⁵Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁶Assistance Publique Hôpitauxde Paris, Paris, France, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Recent studies have highlighted the potential of composite scores such as the DAPSA for assessing peripheral arthritis in axSpA and pSpA. However, the swollen…
Abstract Number: 2124 • ACR Convergence 2025
Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)
Eileen Rife¹, Guihua Zhai², Mekibib Altaye³, Jennifer Andringa⁴, Hermine Brunner⁵, Scott Canna⁶, Lauren Henderson⁷, Yukiko Kimura⁸, Scott Lieberman⁹, Mona Riskalla¹⁰, Tiphanie Vogel¹¹, Holly Wobma¹² and Grant Schulert⁵, ¹University of Alabama at Birmingham, birmingham, AL, ²UAB, Birmingham, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Boston Children's Hospital, Watertown, MA, ⁸Hackensack Meridian School of Medicine, New York, NY, ⁹University of Iowa, Iowa City, IA, ¹⁰University of Minnesota Masonic Children's Hospital, Minneapolis, MN, ¹¹Baylor College of Medicine, Houston, TX, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The physician global assessment of lung disease (PGALD) is a recently proposed disease activity measure for patients with systemic juvenile idiopathic arthritis-associated lung disease…
Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1396 • ACR Convergence 2025
Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease
Esra Sevimli¹, Berceste Polat², Busra Sari³, Can Akmansoy², Burcu Aksoy⁴, Omur Mumcu⁵, Hatice Kalender³, Aysegul Avcu⁶, Mustafa Erdogan⁷, Nur Sisman⁸, Farida Fortune⁹, Gonca Mumcu¹⁰ and Nevsun Inanc⁷, ¹¹Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ²Marmara University, Faculty of Dentistry, Istanbul, Turkey, ³Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Institute of Postgraduate Education, Department of Health Management, Istanbul, Turkey, ⁵Yeditepe University, Faculty of Dentistry, Istanbul, Turkey, ⁶Marmara University, Istanbul, Turkey, ⁷Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁹Barts and The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, London, United Kingdom, ¹⁰Faculty of Dentistry, Istanbul Okan University, Istanbul, Turkey
Background/Purpose: Patient-centred care and improvement of daily life are the main components in chronic disease management. The aim of the study was to determine associations…
Abstract Number: 1159 • ACR Convergence 2025
IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Hadeel Abdul-Rehman¹, Karen Gambina² and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Columbia University Medical Center, Islip, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Adult-Onset Still’s Disease (AOSD) is a rare systemic inflammatory disease. Interleukin-18 (IL-18) levels are significantly elevated in AOSD patients¹ and may be a promising…
Abstract Number: 0834 • ACR Convergence 2025
Heterogeneity in the Association of Genetic Risk for Rheumatoid Arthritis and Resultant Rheumatoid Arthritis Phenotypes
Thomas Riley¹, Austin Wheeler², Bryant England², Grant Cannon³, Brian Sauer⁴, Gary Kunkel⁵, Katherine Wysham⁶, Beth Wallace⁷, Paul Monach⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Geoffrey Thiele², Rui Xiao¹, Scott Damrauer¹⁴, Michael Levin¹⁴, Michael George¹, Ted Mikuls² and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁷Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁸VA Boston Healthcare System, Boston, MA, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: The impact of genetic risk factors on rheumatoid arthritis (RA) phenotype is incompletely understood. Comparing individual genetic variants associated with RA susceptibility to a…
Abstract Number: 0473 • ACR Convergence 2025
A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA
Jay Tuttle¹, Kirstin Griffing², Mark Genovese², Hyungmin Rha², So Young Park², Pia Yachi¹, Ajay Nirula¹, LANCE PFEIFER², Tami Jo Rayle², Jesus Abraham Simón-Campos³, Clifton Bingham⁴, Kevin Winthrop⁵, Daniel Aletaha⁶, Iain McInnes⁷, Yu Xue⁸, Yoshiya Tanaka⁹, Roy Fleischmann¹⁰, Paul Emery¹¹ and Michael Weinblatt¹², ¹Lilly Biotechnology Center, San Diego, CA, ²Eli Lilly and Company, Indianapolis, IN, ³Köhler & Milstein Research, UADY School of Medicine, Merida, Yucatan, Mexico, ⁴Johns Hopkins University, Baltimore, MD, ⁵Oregon Health & Science University, Portland, OR, ⁶Medical University Vienna, Wien, Austria, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ⁹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Peresolimab, a humanized IgG1 mAb, activates programmed cell death protein 1. In a phase 2a study, peresolimab demonstrated efficacy in participants (pts) with RA…
Abstract Number: 0295 • ACR Convergence 2025
Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Manali Sarkar¹, Meera Shah², Vincenzo Venerito³, Vikas Agarwal⁴ and Latika Gupta⁵, ¹Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ²Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Fatigue significantly impacts quality of life in idiopathic inflammatory myopathies (IIM) but remains poorly understood. This study aimed to identify the key determinants of…
Abstract Number: 2649 • ACR Convergence 2025
Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Bernard Rubin², Mohan Purushothaman², Wade DeJager³, Susan Macwana⁴, Joel Guthridge⁴, Stan Kamp⁴, Nancy Redinger⁴, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yangfen Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane Kamen⁸, Jill Buyon⁹, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Medical University of South Carolina, Johns Island, SC, ⁹NYU Grossman School of Medicine, New York, NY
Background/Purpose: Immune dysregulation propels systemic lupus erythematosus (SLE) pathogenesis. Capturing it as lab-based screening tests could help prioritize SLE patients for early intervention and proactive…
Abstract Number: 2322 • ACR Convergence 2025
Gender-related Differences in Peripheral and Axial Spondyloarthritis
Mehmet Tuncay Duruöz¹, Halise Hande Gezer¹, İlknur Aktaş², Servet Akar³, Nilay Şahin⁴, Özgür Akgül⁵, Sami Hizmetli⁶, Meltem Alkan Melikoğlu⁷, Umut Kalyoncu⁸, Erhan Çapkın⁹, fatma Gülçin Ural¹⁰, Figen Yılmaz¹¹, Sebnem ATAMAN¹² and İlhan Sezer¹³, ¹Marmara University Medical School PMR Department, Rheumatology Division, Istanbul, Turkey, ²Istanbul Fatih Sultan Mehmet Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, ³Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey, ⁴Balikesir University School of Medicine, PMR, Turkey, Balıkesir, Turkey, ⁵Manisa Celal Bayar University School of Medicine, Rheumatology, Turkey, Manisa, Turkey, ⁶Sivas Cumhuriyet University School of Medine, Rheumatology, Turkey, Sivas, Turkey, ⁷Erzurum Atatürk University School of Medicine, Rheumatology, Turkey, Erzurum, Turkey, ⁸Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁹Karadeniz Teknik University School of Medicine, PMR, Turkey, Trabzon, Turkey, ¹⁰Ankara Yildirim Beyazit University School of Medicine, PMR, Turkey, Ankara, Turkey, ¹¹Istanbul Sisli Etfal Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, ¹²Ankara University School of Medicine, Rheumatology, Turkey, Ankara, Turkey, ¹³Akdeniz University School of Medicine, Rheumatology, Turkey, Antalya, Turkey
Background/Purpose: This study sought to compare clinical characteristics between female and male patients with spondyloarthritis (SpA) in a Turkish population.Methods: This study included 489 peripheral…
Abstract Number: 2096 • ACR Convergence 2025
Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial
Kimberly Hayes¹, Bryant England², Katherine Wysham³, Mercedes Quinones⁴, Marianna Olave⁵, Sarah Wetzel⁶, Hannah Brubeck⁷, Rachel Gillcrist⁸, Criswell Lavery⁹, Natalie Keller¹⁰, Bibiana Ateh¹¹, Bridget Kramer², Rui Xiao⁹, Kaitian Jin⁹, Alexis Ogdie¹², Daniel K. White¹³, Tuhina Neogi¹⁴, Carla Scanzello⁹ and Joshua Baker⁹, ¹Teachers College, Columbia University, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Washington DC VA Medical Center, Bethesda, MD, ⁵Brown University, Philadelphia, PA, ⁶Drexel University, Pittsburgh, PA, ⁷VA Puget Sound Health Care System, Seattle, WA, ⁸Dartmouth College, Lebanon, NH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰University of Oklahoma, Philadelphia, PA, ¹¹Washington VA Medical Center, Washington, District of Columbia, ¹²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ¹³University of Delaware, Newark, DE, ¹⁴Boston University School of Medicine, Boston, MA
Background/Purpose: Promotion of physical activity is important in the management of knee osteoarthritis (KOA), though effective strategies for behavioral change to promote exercise are lacking.…
Abstract Number: 1531 • ACR Convergence 2025
Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Ioannis Parodis¹, Julius Lindblom², Roger A. Levy³, Alexander Tsoi¹, Margherita Zen⁴, Dionysis Nikolopoulos⁵, Munther Khamashta⁶, Ryan Tomlinson⁷, Anca Askanase⁸, Ronald van Vollenhoven⁹ and Mandana Nikpour¹⁰, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁴University of Padua, Department of Medicine, Division of Rheumatology, Padua, Italy, ⁵Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁶GSK, Medical Affairs, Dubai, United Arab Emirates, ⁷GSK, Development – R&D, Collegeville, PA, ⁸Columbia University Medical Center, New York, NY, ⁹Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹⁰University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: An integrated post hoc analysis of five Phase 3 trials in adults with SLE showed greater benefit of belimumab (BEL) than placebo (PBO), plus…
Abstract Number: 1375 • ACR Convergence 2025
86-96% of rheumatoid arthritis (RA) patients with RA who have 0 or 1 swollen joint or tender joint but are classified as moderate/high on RA indices have 1-9 comorbidities recognized on a multidimensional health assessment questionnaire (MDHAQ)
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) guidelines suggest management according to “treat-to-target,” with escalation of treatment in patients with moderate/high (M/H) DAS28 (disease activity score 28) or…

« Previous Page
1
…
3
4
5
6
7
…
112
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].